Skip to content

Developed with the lowest effective concentration of pilocarpine to minimize side effects experienced by presbyopia patients1

Scrapbooking 2

 

Safety that stands apart

Across clinical trials, every Qlosi adverse event stayed in the single digits

Qlosi demonstrated single-digit incidence for all reported adverse events across clinical studies.


This chart does not reflect a head-to-head study of Qlosi, Vuity® or VizzTM.
 

Qlosi1,2

(0.3% Pilocarpine)

Vuity"3,6"

(1.06% Pilocarpine)

VIZZTM7,8*

(1.44% Aceclidine)

Concentration of Primary Active
0.4% Pilocarpine HCI
1.25% Pilocarpine HCI
1.75% Aceclidine HCI
Common Adverse Reactions*
 
 
 
Non-ocular AEs

Headache

21 (6.8%)
4.8% moderate
56 (14.9%)
16% moderate or severe
30 (13%)
4% severe, 7% moderate
Ocular AEs
 
 
 

Instillation site pain/irritation

18 (5.8%)
16 (4.3%)
47 (20%)

Blurred vision

11 (3.6%)
17 (4.5%)
Not publicly available

Visual impairment

3 (1.0%)
19 (5.1%)
37 (16%)†

Conjunctival hyperemia

5 (1.6%)
0 (0.0%)
19 (8%)

Ocular hyperemia

0 (0.0%)
0 (0.0%)
16 (7%)
 
 
VUITY PI
VIZZ PI

*Most common adverse reactions defined as adverse reactions reported in ≥5% of patients.

†Dim vision reported.

AEs=adverse events

Vizz™ is a trademark of LENZ Therapeutics, Inc. Vuity® is a registered trademark of AbbVie Inc.

 

Qlosi’s unique 0.4% concentration was specifically designed to optimize near-vision efficacy and minimize side effects.1,2,9,10

 

See more

Qlosi’s safety profile has remained consistent across clinical studies and real-world use, with 0 reported cases of retinal detachment (RD) to date.1

Retinal detachment (RD) is not unique to Qlosi—it’s a rare class effect associated with all miotics.1,11 Patients should be evaluated prior to prescribing.1,3,4,11

Qlosi’s lower concentration and controlled dosing help minimize the risk factors historically seen with older, higher-dose therapies.1,3,7

RD concerns are typically linked to factors not associated with Qlosi12:

  • Historical use of higher-concentration miotics

  • Initial use by non-ECPs using inconsistent patient monitoring

In clinical trials of Qlosi1:

  • No cases of RD were reported

  • No elevated or disproportionate RD incidence observed

In early real-world use12:

  • No RD cases have been reported in the first [7] months of availability (source forthcoming)

Examination of the retina is advised prior to initiating therapy.

Help patients see the difference with Qlosi

Save today

Important Safety Information

Expand

Indication and Usage

 

QlosiTM is indicated for treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the instillation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information: here

References

  1. Qlosi [package insert] Ponte Vedra, FL. Orasis Pharmaceuticals.
  2. Holland E, Karpecki P, Fingeret M, et al, Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  3. VUITY PI [package insert]. North Chicago, IL: AbbVie Inc.
  4. Vuity website: https://vuitypro.com/safety. Accessed January 10, 2025.
  5. Waring GO, Price FW, Wirta D. Safety and efficacy of AGN-190584 in individuals with presbyopia: the GEMINI 1 phase 3 randomized clinical trial. JAMA Ophthalmol. 2022;140(4):363-371. doi:10.1001/jamaophthalmol.2022.0059
  6. Waring GO IV, Moshirfar M, Lievens CW, Liu H, Zheng S, Robinson MR. Twice- vs once-daily pilocarpine HCl 1.25% for presbyopia: safety profiles from randomized, masked, controlled, prospective, phase 3 studies. Presented at: American Society of Cataract and Refractive Surgery (ASCRS) 2023 Annual Meeting; May 5-8, 2023; San Diego, CA. 
  7. VIZZ [prescribing information]. Solana Beach, CA; LENZ Therapeutics, Inc. 2025.
  8. LENZ Therapeutics, Inc. LENZ Therapeutics Corporate Presentation. Available at: https://ir.lenz-tx.com/news-events/presentations. Accessed November 17, 2025.
  9. Mitra AK, Mikkelson TJ. Mechanism of transcorneal permeation of pilocarpine. J Pharm Sci. 1988;77(9):771-775. doi:10.1002/jps.2600770911
  10. Anderson RA, Cowle JB. Influence of pH on the effect of pilocarpine on aqueous dynamics. Br J Ophthalmol. 1968;52(8):607-611. doi:10.1136/bjo.52.8.607
  11. Ludwig CA, Vail D, Al-Moujahed A, et al. Epidemiology of rhegmatogenous retinal detachment in commercially insured myopes in the United States. Sci Rep. 2023;13:9430. doi:10.1038/s41598-023-35520-x
  12. Data on file. Orasis 2025.

.